This study is looking at a medicine called pegozafermin to see if it's safe and works well for people with a liver condition called compensated cirrhosis due to MASH. MASH stands for metabolic-associated steatohepatitis, a type of liver disease. In this study, your liver condition should be stage F4, which is the most advanced stage of liver scarring but still compensated, meaning the liver is still functioning. To join, you need to be between 18 and 75 years old, have at least one metabolic risk factor (like high blood pressure or diabetes), and have a certain body weight.

If you have liver problems other than MASH, severe diabetes, or a history of liver cancer, you cannot participate. The study involves taking medicine and regular check-ups to monitor your health. Participants must also have stable vitamin E intake if they are using it.

• Participants must be available for regular health check-ups.
• Compensation might be available for participants.
• Check if your current medications or conditions allow you to participate.